Cohance Lifesciences Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The net profit of Cohance Lifesciences Ltd changed from ₹ 153.48 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -76.73% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Cohance Lifesciences Ltd is 16,431 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,328 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹429.5. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹30.34.

How do dividend payouts of Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.